NeuroSense Therapeutics resumes PrimeC ALS drug development in Canada.

NeuroSense Therapeutics has resumed regulatory advancement in Canada for its treatment, PrimeC, in amyotrophic lateral sclerosis (ALS). Following a productive discussion with Health Canada, the company is now preparing for a pre-NDS meeting in April 2026, with a potential NDS submission by mid-2026. The company's proposed next steps align with Health Canada's expectations, and additional clinical data has been generated, with further supportive analyses underway.